Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722657 | 0.92 | PTGS2 (0.37) | KIF11PTGS2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6720055 | 0.91 | PTGS2 (0.40) | KIF11PTGS2PTGS1 | |
| SCHEMBL6721871 | 0.88 | PTGS2 (0.40) | PTGS2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL6730269 | 0.88 | PIK3CD (0.38) | PTGS2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL6725990 | 0.86 | PTGS2 (0.40) | PTGS2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL6734334 | 0.86 | NR1H2 (0.36) | KIF11PTGS2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6726121 | 0.85 | PTGS2 (0.40) | PTGS2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL6718571 | 0.85 | PTGS2 (0.37) | PTGS2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL6729465 | 0.85 | PTGS2 (0.35) | PTGS2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL6718868 | 0.85 | PTGS2 (0.44) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| EP-1296971-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001081332-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | KIF11 4773/4885PTGS2 5/4885PIK3CD 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.